Posttransplant cyclophosphamide–containing prophylaxis correlated with lower aGVHD risk than tacrolimus/methotrexate, and ATG/alemtuzumab use contributed to risk estimation. Clinical utility includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results